<DOC>
	<DOC>NCT01190436</DOC>
	<brief_summary>The aim of this 12-week, multicenter, interventional, prospective, open-label and single-arm study is to evaluate the safety and efficacy of 5 milligram per day (mg/day) and 10 mg/day bisoprolol in Filipino hypertensive subjects with diabetes as monotherapy or as an add-on therapy.</brief_summary>
	<brief_title>A 12-week, Multicentric Study to Evaluate the Safety and Efficacy of Bisoprolol in Filipino Hypertensive Subjects With Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Bisoprolol</mesh_term>
	<criteria>Adult subjects with hypertension, either newly diagnosed or treated but currently uncontrolled as defined by Joint National Committee (JNC) 7 for subjects with Type 2 diabetes mellitus (T2DM) (that is, greater than or equal to [&gt;=] 130/80 mmHg) Aged at least 18 years old Diagnosed with T2DM and already on antidiabetic therapy, and with glycosylated hemoglobin of less than 7 percent Subjects who were already on betablocker therapy at the time of recruitment Subjects with heart rate of at most 60 beats per minute (bpm) at rest Subjects with secondary hypertension, congenital heart disease, coronary artery disease, peripheral arterial disease or congestive heart failure in any stage Subjects with coronary conduction disorders (bundle branch block) Subjects with signs of definitive target organ damage consistent with World Health Organization (WHO) Stage III or with severe renal or hepatic disease Subjects who are pregnant or expect to be pregnant within the 24week study period Subjects on oral contraceptives Subjects with asthma or a history of asthma Subjects with documented severe renal disease Subjects on antineoplastic drugs</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Hypertension</keyword>
	<keyword>Diabetes Mellitus</keyword>
	<keyword>Bisoprolol</keyword>
</DOC>